These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7200396)

  • 1. Acute nephrotoxicity following cis-dichlorodiammine-platinum.
    Bitran JD; Desser RK; Billings AA; Kozloff MF; Shapiro CM
    Cancer; 1982 May; 49(9):1784-8. PubMed ID: 7200396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. cis-Diamminedichloroplatinum-induced hypomagnesemia and renal magnesium wasting.
    Bell DR; Woods RL; Levi JA
    Eur J Cancer Clin Oncol; 1985 Mar; 21(3):287-90. PubMed ID: 4040020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal magnesium wasting and hypocalciuria in chronic cis-platinum nephropathy in man.
    Mavichak V; Coppin CM; Wong NL; Dirks JH; Walker V; Sutton RA
    Clin Sci (Lond); 1988 Aug; 75(2):203-7. PubMed ID: 3409636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cis-diamminedichloroplatinum (DDP) induced acute renal failure (ARF): attempts at amelioration.
    Chopra S; Kaufman J; Flamenbaum W
    Clin Exp Dial Apheresis; 1983; 7(1-2):25-35. PubMed ID: 6684010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal complications of cis-diamminedichloroplatinum.
    Nitschke R
    Ann Clin Lab Sci; 1981; 11(5):392-6. PubMed ID: 7199273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute renal tubular dysfunction following cis-dichlorodiammine platinum therapy.
    Davis S; Kessler W; Haddad BM; Maesaka JK
    J Med; 1980; 11(2-3):133-41. PubMed ID: 6931873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal tubular function in patients treated with high-dose cisplatin.
    Daugaard G; Abildgaard U; Holstein-Rathlou NH; Bruunshuus I; Bucher D; Leyssac PP
    Clin Pharmacol Ther; 1988 Aug; 44(2):164-72. PubMed ID: 2840230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal failure and platinum pharmacokinetics in three patients treated with cis-diamminedichloroplatinum(II) and whole-body hyperthermia.
    Gerad H; Egorin MJ; Whitacre M; Van Echo DA; Aisner J
    Cancer Chemother Pharmacol; 1983; 11(3):162-6. PubMed ID: 6685578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nephrotoxicity of cis-diamminedichloroplatinum with or without ifosfamide in cancer treatment.
    Hacke M; Schmoll HJ; Alt JM; Baumann K; Stolte H
    Clin Physiol Biochem; 1983; 1(1):17-26. PubMed ID: 6383688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin.
    Schilsky RL; Anderson T
    Ann Intern Med; 1979 Jun; 90(6):929-31. PubMed ID: 375794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical investigation of cis-platinum nephrotoxicity in 244 cases of primary lung cancer].
    Soejima A; Inoue T; Suzuki M; Waku M; Nakabayashi K; Kitamoto K; Nagasawa T
    Nihon Jinzo Gakkai Shi; 1992 Jul; 34(7):801-6. PubMed ID: 1479719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial effects of short-term calorie restriction against cisplatin-induced acute renal injury in aged rats.
    Ning YC; Cai GY; Zhuo L; Gao JJ; Dong D; Cui SY; Shi SZ; Feng Z; Zhang L; Sun XF; Chen XM
    Nephron Exp Nephrol; 2013; 124(3-4):19-27. PubMed ID: 24401898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. cis-diamminedichloroplatinum(II) nephrotoxicity: tubular function after rescue with sodium diethyldithiocarbamate in rats.
    Elliott WC; Newcom SR; Houghton DC; Baines-Hunter J; Bennett WM
    Cancer Res; 1983 Aug; 43(8):3759-62. PubMed ID: 6305493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical multivariate statistical analysis of nephrotoxicity induced by cisplatin].
    Ding DC
    Zhonghua Zhong Liu Za Zhi; 1992 Jan; 14(1):64-6. PubMed ID: 1396050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Silymarin Administration on Cisplatin Nephrotoxicity: Report from A Pilot, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.
    Shahbazi F; Sadighi S; Dashti-Khavidaki S; Shahi F; Mirzania M; Abdollahi A; Ghahremani MH
    Phytother Res; 2015 Jul; 29(7):1046-53. PubMed ID: 25857366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe nephrotoxicity: a probable complication of cis-dichlorodiammineplatinum (II) and cephalothin-gentamicin therapy.
    Salem PA; Jabboury KW; Khalil MF
    Oncology; 1982; 39(1):31-2. PubMed ID: 7199128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
    Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
    Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The incidence of cisplatin nephrotoxicity post hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery.
    Hakeam HA; Breakiet M; Azzam A; Nadeem A; Amin T
    Ren Fail; 2014 Nov; 36(10):1486-91. PubMed ID: 25155314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of cis-platinum nephrotoxicity in a high-risk patient.
    Donadio C; Lucchesi A; Gadducci A
    Ren Fail; 1996 Jul; 18(4):691-5. PubMed ID: 8875699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity, induction of cross-resistance, and nephrotoxicity of a new platinum analogue, cis-1,1-diaminomethylcyclohexaneplatinum(II) sulfate, and of cis-diamminedichloroplatinum(II) in an immunocytoma model in the LOU/M rat.
    de Jong WH; Steerenberg PA; Vos JG; Bulten EJ; Verbeek F; Kruizinga W; Ruitenberg EJ
    Cancer Res; 1983 Oct; 43(10):4927-34. PubMed ID: 6683993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.